In-vitro study of formulation and evaluation of nanosuspension of tamoxifen


  • Somasekhar M. Reddy Department of Pharmacology, Bhaskara Medical College, Moinabad, Rangaredy, Hyderabad, Telangana, India
  • Navispaul N. Sriganth Department of EEE, Saveetha School of Engineering, Thandalam Chennai, Tamilnadu, India
  • Chandra S. Kumar Department of Pathology, ESIC, Sanath Nagar, Hyderabad, Telangana, India
  • Santosh C. Gursale Department of Pharmacology, B.K.L. Walawalkar Rural Medical College, Sawarde, Ratnagiri, Maharashtra, India
  • Vijay V. Ragavan Director, Saveetha University, Thandalam, Chennai, Tamilnadu, India



Electron microscopy, Nanosuspension, Tamoxifen, Transmission


Background: Nanosuspension technology has been developed as a promising candidate for efficient delivery of hydrophobic drugs. It could maintain the required crystalline state of the drug with reduced particle size, leading to an increased reporting on dissolution rate and therefore improved bioavailability.

Methods: In this paper, we report on the preparation of Tamoxifen nanosuspension by high-pressure homogenization (HPH). The aim is to obtain a stable nanosuspension with an increased drug saturation solubility and dissolution velocity. The morphology and particle size distribution of the modified nanosuspensions were characterized by the means of several analyses that included: transmission electron microscopy (TEM), polarized light microscopy (PLM), scanning electron microscopy, differential scanning calorimetry (DSC) and powder X- ray diffractometry (XRD).

Results: HPH was employed to produce aqueous drug nanosuspensions with fine solubility and dissolution properties, which render the produced particles stable up to one month. In addition, the prepared nanosuspensions possessed a high drug-loading efficiency (10%). The recoded zeta potential values (≈ -27 mV) indicated that the prepared nanosuspensions possess a higher degree of long-term stability. TEM data showed narrow size distribution with average size 322.7 nm. Morphologically, as indicated from results, the produced nanosuspensions have a homogenous distribution even after redispersion, indicating the stability of the product.

Conclusions: It was possible to obtain Tamoxifen nanosuspensions with fine solubility and dissolution properties. Nanosuspensions possessed a high drug- loading (10%), which could reduce the dosage administration and gastrointestinal side effects. HPH can be employed to produce aqueous drug nanosuspensions that are stable up to one month. Aqueous nanosuspension can be converted to dry nanocrystals by lyophilization which offer superior physicochemical properties.


Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Advanced drug delivery reviews. 2001 Mar 23;47(1):3-19.

Möschwitzer J, Achleitner G, Pomper H, Müller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. European Journal of Pharmaceutics and Biopharmaceutics. 2004 Nov 1;58(3):615-9.

Mouridsen H. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-76.

De Lima GR, Facina G, Shida JY, Chein MB, Tanaka P, Dardes RC, Jordan VC, Gebrim LH. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. European Journal of Cancer. 2003 May 1;39(7):891-8.

Mirzajani F, Rafati H, Atyabi F. Fabrication of biodegradable poly (d, l-lactide-co-glycolide) nanoparticles containing tamoxifen citrate. Iranian Polymer Journal. 2010;19 (6):437-46.

Li Y, Dong L, Jia A, Chang X, Xue H. Preparation and characterization of solid lipid nanoparticles loaded traditional Chinese medicine. International journal of biological macromolecules. 2006 May 30;38(3-5):296-9.

Jacobs C, Kayser O, Müller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. International journal of pharmaceutics. 2000 Mar 10;196(2):161-4.

Lindfors L, Skantze P, Skantze U, Rasmusson M, Zackrisson A, Olsson U. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir. 2006 Jan 31;22(3):906-10.

Dubernet C. Thermoanalysis of microspheres. Thermochim. Acta. 1995;248:259-69.

Corrigan DO, Healy AM, Corrigan OI. The effect of spray drying solutions of bendroflumethiazide/polyethylene glycol on the physicochemical properties of the resultant materials. International Journal of Pharmaceutics. 2003 Aug 27;262(1-2):125-37.

Hancock BC, Carlson GT, Ladipo DD, Langdon BA, Mullarney MP. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. International Journal of Pharmaceutics. 2002 Jul 8;241(1):73-85.

Böhm BH, Müller RH. Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs. Pharmaceutical science & technology today. 1999 Aug 1;2(8):336-9.

Müller RH, Jacobs C, Kayser O. Nanosuspensions for the Formulation of Poorly Soluble Drugs In: F. Nielloud and G. Marti-Mestres. Pharmaceutical Emulsions and Suspensions. 2000:383-407.

RA Nash. Suspensions, In: J Swarbrick, JC Boylan (ed), Encyclopedia of pharmaceutical technology, 2nd Edition; New York: Marcel Dekker; 2002:3:2045-3032.

Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drug I: Preparation by size reduction technique. Int. J. Pharm. 1998;160:229-37.

Dianrui Z, Tianwei T, Lei G, Wenfa Z, Peng W. Preparation of Azithromycin Nanosuspensions by High Pressure Homogenization and its Physicochemical Characteristics Studies, Drug Development and Industrial Pharmacy. 2007;3(5):569-75.

Soo PL, Cho J, Grant J, Ho E, Miller MP, Allen C. Drug release mechanism of paclitaxel from a chitosan- lipid implant system: Effect of swelling, degradation and morphology, European Journal of Pharmaceutics and Biopharmaceutics. 2008;69:149-57.




How to Cite

M. Reddy, S., N. Sriganth, N., S. Kumar, C., C. Gursale, S., & V. Ragavan, V. (2018). In-vitro study of formulation and evaluation of nanosuspension of tamoxifen. International Journal of Basic & Clinical Pharmacology, 7(5), 926–934.



Original Research Articles